cyclophosphamide + rituximab placebo

This refers to a clinical trial control arm or comparator group in which patients receive cyclophosphamide plus a placebo in place of rituximab. Cyclophosphamide is an alkylating agent that crosslinks DNA, leading to cell death, and is used as an immunosuppressant and chemotherapeutic. In this context, the "rituximab placebo" indicates that patients do not receive active rituximab (a monoclonal antibody targeting CD20 on B cells), but instead receive a non-active substitute for blinding purposes. This regimen is typically used as part of randomized controlled trials comparing the efficacy and safety of cyclophosphamide alone versus combination therapy with cyclophosphamide and rituximab for diseases such as ANCA-associated vasculitis.